acrogranin Activators
Acrogranin, also known as pregnancy-associated glycoprotein (PAG), is a glycoprotein predominantly expressed in trophoblast cells of the placenta during pregnancy. Its precise function remains a subject of ongoing research; however, emerging evidence suggests that acrogranin plays a crucial role in regulating placental development and function, as well as maternal-fetal communication. One of the key functions attributed to acrogranin is its involvement in modulating immune responses at the maternal-fetal interface. It is believed to contribute to maternal immune tolerance towards the semi-allogeneic fetus by promoting the suppression of maternal immune responses against fetal antigens, thus stopping rejection of the embryo. Additionally, acrogranin has been implicated in trophoblast invasion and migration, processes essential for proper placental development and establishment of adequate blood flow to support fetal growth and development.
The activation of acrogranin involves intricate molecular mechanisms that are yet to be fully elucidated. It is hypothesized that various signaling pathways, including those mediated by growth factors and cytokines, contribute to the regulation of acrogranin expression and activity. For instance, studies have suggested that factors such as epidermal growth factor (EGF) and transforming growth factor-beta (TGF-β) may stimulate acrogranin expression in trophoblast cells, through the activation of specific intracellular signaling cascades. Moreover, the activation of transcription factors such as STAT3 and NF-κB has been implicated in the regulation of acrogranin gene expression, further highlighting the complexity of its activation mechanisms. Additionally, post-translational modifications, such as glycosylation, may modulate the stability and function of acrogranin, thereby influencing its activity in placental physiology. Overall, while the precise mechanisms governing acrogranin activation remain to be fully elucidated, current research suggests that it plays a critical role in placental development and maternal-fetal immune tolerance, with its activation likely orchestrated by a network of signaling pathways and regulatory molecules.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin is an adenylate cyclase activator that directly influences acrogranin by activating the cAMP/PKA signaling pathway. Forskolin-induced cAMP elevation leads to PKA activation, affecting acrogranin expression and function in cellular processes. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram is a phosphodiesterase 4 (PDE4) inhibitor that indirectly modulates acrogranin by enhancing cAMP levels. Rolipram-induced PDE4 inhibition leads to reduced cAMP degradation, affecting acrogranin expression and function in cellular processes. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-selective phosphodiesterase inhibitor that indirectly influences acrogranin by elevating cAMP levels. IBMX-induced phosphodiesterase inhibition leads to reduced cAMP degradation, affecting acrogranin expression and function in cellular processes. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $90.00 $350.00 | 16 | |
Cilostamide is a selective phosphodiesterase 3 (PDE3) inhibitor that indirectly modulates acrogranin by enhancing cAMP levels. Cilostamide-induced PDE3 inhibition leads to reduced cAMP degradation, affecting acrogranin expression and function in cellular processes. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
Zaprinast is a phosphodiesterase 5 (PDE5) inhibitor that indirectly influences acrogranin by enhancing cGMP levels. Zaprinast-induced PDE5 inhibition leads to reduced cGMP degradation, affecting acrogranin expression and function in cellular processes. | ||||||
Piclamilast | 144035-83-6 | sc-478653 | 5 mg | $300.00 | ||
Piclamilast is a selective phosphodiesterase 4 (PDE4) inhibitor that indirectly modulates acrogranin by enhancing cAMP levels. Piclamilast-induced PDE4 inhibition leads to reduced cAMP degradation, affecting acrogranin expression and function in cellular processes. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $97.00 $224.00 | 30 | |
8-Bromo-cAMP is a cell-permeable analog of cAMP that directly influences acrogranin by activating the cAMP/PKA signaling pathway. 8-Bromo-cAMP-induced cAMP elevation leads to PKA activation, affecting acrogranin expression and function in cellular processes. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $162.00 $683.00 | 7 | |
Milrinone is a phosphodiesterase 3 (PDE3) inhibitor that indirectly modulates acrogranin by enhancing cAMP levels. Milrinone-induced PDE3 inhibition leads to reduced cAMP degradation, affecting acrogranin expression and function in cellular processes. | ||||||
YC-1 | 170632-47-0 | sc-202856 sc-202856A sc-202856B sc-202856C | 1 mg 5 mg 10 mg 50 mg | $32.00 $122.00 $214.00 $928.00 | 9 | |
YC-1 is a stimulator of soluble guanylate cyclase (sGC) that indirectly influences acrogranin by enhancing cGMP levels. YC-1-induced sGC stimulation leads to increased cGMP production, affecting acrogranin expression and function in cellular processes. | ||||||
8-Bromo-cGMP | 51116-01-9 | sc-200316 sc-200316A | 10 mg 50 mg | $102.00 $347.00 | 7 | |
8-Bromo-cGMP is a cell-permeable analog of cGMP that directly influences acrogranin by activating the cGMP/PKG signaling pathway. 8-Bromo-cGMP-induced cGMP elevation leads to PKG activation, affecting acrogranin expression and function in cellular processes. | ||||||